Tekton Research Selects Todata’s SiteGrades and Tod AI as Enterprise Business Intelligence Solution
OMAHA, Neb., Nov. 5, 2025 /PRNewswire/ -- Tekton Research, a leading multispecialty clinical trial site organization conducting Phase 1-4 trials,...
Vaccine
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT /...
Dalan Animal Health Announces Successful Efficacy Trials for its Honeybee Vaccine, Advancing Toward Full USDA Licensure
The successful vaccine trials for honeybees, together with recent breakthrough results from clinical trials for disease prevention in shrimp, further...
Proven Performance Secures Odyssey Recompete of Intestinal Infection Research with Walter Reed Army Institute of Research
WAKEFIELD, Mass., Nov. 4, 2025 /PRNewswire/ -- Odyssey, a leading provider of integrated defense capabilities and technologies, announced today it...
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual...
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules
Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech...
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has...
Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and...
Disrupting Healthcare: Dr. Jay Greenstein’s AI Rewards Patients for Healing Themselves
Dr. Jay Greenstein, CEO of Embody Health, joins the Disruption/Interruption podcast to discuss how fusing AI with behavioral science and...
Saama Unveils Industry-first AI-Powered Tables, Listings, and Figures (TLF) Analyzer to Transform Clinical Study Reporting
New multi-modal GenAI solution accelerates report authoring and introduces breakthrough "Figures-to-Text" interpretation for faster, context-aware clinical insights CAMPBELL, Calif., Oct....
Evaxion raises $7.2 million, extending cash runway to second half of 2027
Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross...
Grupo Elfa and NUPCO sign agreement to support Saudi healthcare ecosystem with high-quality medical innovation and AI expertise
Collaboration will leverage the exchange of expertise, develop innovative supply-chain models, and assess technology-driven solutions to improve product availability Strategic...
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000...
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
COPENHAGEN, Denmark, October 29, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby...
ObvioHealth and Vaxxas Sign Multi-Year Agreement to Power Needle-Free Vaccination Technology Trials with ObvioGo®
NEW YORK, Oct. 28, 2025 /PRNewswire/ -- ObvioHealth, a global leader in digital clinical trial solutions, announced that it has signed...
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for...
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting...
BioNTech to Host Innovation Series R&D Day on November 11, 2025
MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of...
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net...